Dear Editor,Despite substantial advances in neonatal medicine, retinopathy of prematurity (ROP) continues to be a serious therapeutic challenge⑴.Visual acuity loss in patients with ROP has been associated with struct...Dear Editor,Despite substantial advances in neonatal medicine, retinopathy of prematurity (ROP) continues to be a serious therapeutic challenge⑴.Visual acuity loss in patients with ROP has been associated with structural retinal abnormalities (including retinal detachment, retinal folds, and pigmentary retinopathy), cataract, glaucoma, and amblyopia due to refractive error or strabismus[2].展开更多
基金Supported in part by the National Institute of Health,Bethesda,Maryland(Grant P30-EY014801)an unrestricted grant to the University of Miami from Research to Prevent Blindness,New York,New York,USA
文摘Dear Editor,Despite substantial advances in neonatal medicine, retinopathy of prematurity (ROP) continues to be a serious therapeutic challenge⑴.Visual acuity loss in patients with ROP has been associated with structural retinal abnormalities (including retinal detachment, retinal folds, and pigmentary retinopathy), cataract, glaucoma, and amblyopia due to refractive error or strabismus[2].
